The superior predictive value of 166Ho-scout compared with 99mTc-macroaggregated albumin prior to 166Ho-microspheres radioembolization in patients with liver metastases



As an alternative to technetium-99m-macroaggregated albumin (99mTc-MAA), a scout dose of holmium-166 (166Ho) microspheres can be used prior to 166Ho-radioembolization. The use of identical particles for pre-treatment and treatment procedures may improve the predictive value of pre-treatment analysis of distribution. The aim of this study was to analyze the agreement between 166Ho-scout and 166Ho-therapeutic dose in comparison with the agreement between 99mTc-MAA and 166Ho-therapeutic dose.


Two separate scout dose procedures were performed (99mTc-MAA and 166Ho-scout) before treatment in 53 patients. First, qualitative assessment was performed by two blinded nuclear medicine physicians who visually rated the agreement between the 99mTc-MAA, 166Ho-scout, and 166Ho-therapeutic dose SPECT-scans (i.e., all performed in the same patient) on a 5-point scale. Second, agreement was measured quantitatively by delineating lesions and normal liver on FDG-PET/CT. These volumes of interest (VOIs) were co-registered to the SPECT/CT images. The predicted absorbed doses (based on 99mTc-MAA and 166Ho-scout) were compared with the actual absorbed dose on post-treatment SPECT.


A total of 23 procedures (71 lesions, 22 patients) were included for analysis. In the qualitative analysis, 166Ho-scout was superior with a median score of 4 vs. 2.5 for 99mTc-MAA (p < 0.001). The quantitative analysis showed significantly narrower 95%-limits of agreement for 166Ho-scout in comparison with 99mTc-MAA when evaluating lesion absorbed dose (− 90.3 and 105.3 Gy vs. − 164.1 and 197.0 Gy, respectively). Evaluation of normal liver absorbed dose did not show difference in agreement between both scout doses and 166Ho-therapeutic dose (− 2.9 and 5.5 Gy vs − 3.6 and 4.1 Gy for 99mTc-MAA and 166Ho-scout, respectively).


In this study, 166Ho-scout was shown to have a superior predictive value for intrahepatic distribution in comparison with 99mTc-MAA.


Treatment planning for radioembolization (known as Selective Internal Radiation Therapy or SIRT) of liver tumors is generally performed with technetium-99m macroaggregated albumin particles (99mTc-MAA). Aside from predicting the lung shunt and (other) non-target embolization, 99mTc-MAA is also used to predict the activity distribution in the liver. Several studies have shown that the value of 99mTc-MAA to predict the distribution of 90Y in the liver is limited [1,2,3,4]. Shape, size, density, and number of injected particles of 99mTc-MAA differ greatly from 90Y-microspheres. This may explain the difference in biodistributions.

As an alternative to the yttrium-90 (90Y)-microspheres, microspheres containing the radioactive element holmium-166 (166Ho) have recently become available (Quiremspheres®, Quirem Medical, Deventer, the Netherlands). The radionuclide 166Ho provides several advantages over 90Y with regard to imaging possibilities. The element holmium itself is paramagnetic and can therefore be visualized—and quantified—on MRI [5, 6]. In addition, 166Ho emits low-energy gamma radiation, which can be used for quantitative SPECT/CT imaging [7]. A scout dose of 166Ho-microspheres (consisting of approximately 3 million microspheres with an activity of 250 MBq) can be used for treatment planning instead of 99mTc-MAA [8]. This has the theoretical benefit of using the exact same 166Ho-microspheres for both procedures. The aim of the current study was to analyze whether the intrahepatic distribution of 166Ho-scout has a better agreement with the 166Ho-therapeutic dose distribution in comparison with 99mTc-MAA.

Materials and methods

Patients and procedures

Patients treated with 166Ho-radioembolization in the phase 1 and phase 2 Holmium Embolization Particles for Arterial Radiotherapy (HEPAR) studies were analyzed ( numbers NCT01031784 and NCT01612325). All patients had unresectable liver metastases from various primaries. The institutional review board approved these studies and all patients provided written informed consent. All patients received treatment planning with the conventional 99mTc-MAA and subsequently with a scout dose of 250 MBq of 166Ho-microspheres (60 mg; approximately 3 million microspheres). Patients were included for analysis if they had received both pre-treatment administrations of 99mTc-MAA and 166Ho-scout before treatment with 166Ho-microspheres.

All radioembolization procedures were performed according to the HEPAR study protocol [9]. Non-target vessels were only coil-embolized in case no safe injection position could be found distal to these non-target vessels. Approximately 150 MBq 99mTc-MAA (0.8 mg, approximately 1.8 million particles, TechneScan LyoMAA; Mallinckrodt Medical B.V., Petten, the Netherlands) was injected. 99mTc-MAA was injected slowly at approximately 5 ml/min. All injections (both 99mTc-MAA and 166Ho-microspheres) were performed with a standard 2.4F or 2.7F microcatheter (Progreat®, Terumo, Japan). At the end of the procedure, the access site in the groin was compressed for hemostasis. 99mTc-MAA injection was followed by planar- and SPECT/CT imaging to check for extrahepatic deposition and excessive lung shunting (> 30 Gy lung absorbed dose). If no contra-indications were found, the patient was scheduled for treatment. In case the 99mTc-MAA procedure had to be repeated because of extrahepatic activity, only the most recent 99mTc-MAA data were used for analysis. No vessels were coil-embolized after the final 99mTc-MAA procedures. On the day of treatment, patients underwent a second treatment-planning procedure in the morning. During this procedure, the injection position(s) from the first treatment planning procedure was mimicked and patients received a scout dose of 250 MBq of 166Ho-microspheres (approximately 3 million microspheres). At the end of the procedure, the catheter and microcatheter were removed. The vascular sheath was left in the groin in order to secure vascular access for the treatment procedure in the afternoon. The sheath was connected to a pressurized bag of saline (for continuous flushing) and secured with sterile tape. This second treatment-planning procedure was again followed by planar imaging and SPECT/CT. If there were no contra-indications for SIRT, patients returned to the angio-suite in the afternoon to receive treatment with 166Ho-microspheres. Catheters were introduced via the vascular sheath that had remained in situ. Again, injection position(s) of the treatment-planning procedures were mimicked. Total treatment activity was planned based on an aimed whole liver absorbed dose of 20, 40, 60, and 80 Gy for patients who were treated in the phase 1 HEPAR study and 60 Gy for patients in the phase 2 HEPAR study [10, 11]. The total number of microspheres injected was the same for all patients (i.e., 600 mg; approximately 30 million microspheres). After injection, the catheters and sheath were removed and a vascular closure device was used for hemostasis.

In order to exclude cases in which differences in injection positions might have influenced distribution, agreement of catheter-tip positions between the three procedures (i.e., 99mTc-MAA, 166Ho-scout, and 166Ho-therapeutic dose) was retrospectively analyzed by three observers (M.S, A.B., and M.L.). These observers independently reviewed the agreement of all injection positions per procedure on digital subtraction angiography images. Agreement was rated on a 4-point scale (1, very poor agreement, difference in catheter tip position > 10 mm; 2, poor agreement, difference 5–10 mm; 3, good agreement, difference 3–5 mm; 4, very good agreement, difference < 3 mm). Only the patients with good or very good agreement (point scale 3 and 4) between all the injection positions were included in this study.

In case of procedures with multiple injection positions, the ratio between the injected activities at each injection position had to be the same for the three procedures. This ratio was based on CT-volumetry (e.g., a 2:1 activity ratio for a right liver lobe of 1000 mL and a left liver lobe of 500 mL). Agreement between the procedures was checked based on the administered activity per injection position, which was corrected for any residual activity. A maximum deviation of 10% between the two pre-treatment and post-treatment injections was accepted.


Pre- and posttreatment SPECT/CT imaging was performed on a dual-headed gamma camera (Forte, Philips Medical Systems, 6 procedures) and a SPECT/CT camera (Symbia 16T, Siemens Health Care, 17 procedures). In all cases, the same scanner was used for pre- and posttreatment SPECT/CT. Pre-treatment 99mTc-MAA SPECT images were acquired on a 512 × 512 matrix (15 procedures) and a 128 × 128 matrix (8 procedures). An energy window of 129.1- to 150.5-keV and a low-energy general-purpose collimator were used. Pre- and post-treatment 166Ho SPECT images (interval; mean 4 days, range 3–6 days) were acquired on a 128 × 128 matrix (22 procedures) and a 512 × 512 matrix (1 procedure) in combination with a 74.9- to 87.1-keV energy window and a medium-energy general-purpose collimator. Imaging was performed with 120 projections over a noncircular orbit of 360° (99mTc-MAA: 30s/projection (Philips) or 20s/projection (Siemens) and 166Ho; 30s/projection). An in-house developed and validated Monte-Carlo-based reconstruction algorithm (Utrecht Monte-Carlo System (UMCS)) intrinsically correcting for attenuation and scatter was used for the reconstruction of the 99mTc-MAA and 166Ho HEPAR I data [12]. The reconstruction of all HEPAR II data was done by using the Siemens Flash3D ordered-subsets expectation maximization (99mTc-MAA; 6 iterations, 8 subsets, 166Ho; 5 iterations 8 subsets). The scatter correction for the HEPAR II 99mTc-MAA data was applied by using the dual energy window method with two adjacent energy windows (both 15% width) and a lower window weight of 0.5. The HEPAR II 166Ho data was reconstructed without scatter correction. For 99mTc-MAA data, a Gaussian post-reconstruction filter of 5 mm in full width at half maximum was also included. Reconstructed voxel sizes were 4.66 × 4.66 × 4.66 mm3 for all Philips images and in the range of 0.70 × 0.70 × 4.03 mm3 to 3.90 × 3.90 × 4.03 mm3 for the Siemens 99mTc-MAA and 4.80 × 4.80 × 4.80 mm3 for the Siemens 166Ho images, respectively.

Qualitative analysis

Two nuclear medicine physicians independently compared the intrahepatic distribution of activity of 99mTc-MAA and 166Ho-scout with the post-treatment 166Ho-therapeutic dose. Image sets of all three SPECT scans were coupled, blinded, and simultaneously presented to the reviewers in our Picture Archive and Communication System (Sectra PACS, Almere, the Netherlands). The post-treatment SPECT was marked “post-treatment” to allow the reviewers to compare it with the other two pre-treatment SPECT scans (which were marked “pre-treatment”). No information was provided regarding the type of pre-treatment scan. To prevent bias, both pre-treatment scans were placed randomly on the screen for each patient. Visual agreement was rated on a 5-point scale (1–5, very poor agreement–very good agreement).

Quantitative analysis

Agreement of intrahepatic distribution was also measured quantitatively. FDG-PET/CT pre-treatment scans were used for segmentation of lesion and liver volumes (volumes of interest, or VOIs). In-house-developed software was used for this purpose (VolumeTool, version 1.6.5.) [13]. Delineation of VOIs was performed manually on FDG-PET images. The normal liver was defined as the whole liver minus tumors. All VOIs were manually registered (non-deformable) to the 99mTc-MAA SPECT, 166Ho-scout SPECT, and 166Ho-therapeutic dose SPECT images (Fig. 1). In order to compensate for co-registration errors and blurring effects, the VOIs were enlarged by a 1-cm margin when measuring the activity. Also, small lesion VOIs with a volume smaller than 10 mL were excluded, because of their higher sensitivity to these errors. The pre-treatment 99mTc-MAA SPECT and 166Ho-scout SPECT and the post-treatment 166Ho-therapeutic dose SPECT were converted into units of 166Ho-activity concentration by normalization of the total number of reconstructed counts to the total administered activity of 166Ho during therapy. This resulted in two predictive amounts of 166Ho (MBq/cm3) for each VOI, based on both pre-treatment SPECT images, in comparison with an actual amount of 166Ho based on post-treatment SPECT. The lesion-absorbed dose was calculated by dividing the activity measured in the lesion VOI plus the 1-cm margin by the volume of that same lesion VOI without the 1-cm margin. Normal liver activity was calculated by subtraction of the measured activity of all lesion VOIs within one patient (including the VOI’s with a volume smaller than 10 mL) without 1-cm margin from the activity of the liver VOI with 1-cm margin. The volume of the normal liver compartment was calculated by subtraction of the total volume of the lesion VOIs without margin from the volume of the liver without margin. Finally, the calculated activity was divided by this volume to calculate the normal liver absorbed dose. No extrahepatic activity distribution and no interval change in liver morphology were assumed. Contribution of gamma radiation was neglected in calculating the absorbed dose. To illustrate clinical implications, the calculated activity concentrations were converted into units of Gray for both the lesion and normal liver segmentations, using a conversion factor of 15.78 ∙ 10−3 Gy/(MBq/kg) assuming a liver density of 1.06 kg/L [10].

Fig. 1

Example of liver and tumor segmentation on FDG-PET (a) and co-registration on 99mTc-MAA (b), 166Ho-scout (c), and 166Ho-therapeutic dose (d) SPECT images. The delineated VOIs were extended with a margin of 1 cm; therefore, each target volume is surrounded by a second line

Statistical analysis

Statistical data analysis was performed using a commercial statistical software package (SPSS for Windows, version 21.0; SPSS Inc.). For the qualitative analysis, medians and interquartile ranges were calculated and the Wilcoxon signed rank test was used to analyze differences in overall agreement scores between both pre-treatment scans and the 166Ho treatment scan. The Weighted Kappa (squared) was calculated to classify the interrater agreement [14, 15].

Bland-Altman plots were used for evaluating agreement between pre- and post-treatment activity biodistributions [16, 17]. The confidence interval of the 95% limits of agreement was used to test the significance of the difference in agreement for both plots. The precision of the 95% limits of agreement was estimated by the number of analyzed procedures or lesions (n), the standard deviation of the differences (s), and the degrees of freedom (n − 1). In this estimation, no corrections were made for any correlation between analyzed lesions within a patient. The 95% confidence intervals were calculated by the multiplication of the standard error (standard error = \( \sqrt{3{\mathrm{s}}^2/n} \)) of the upper and lower 95% limit of agreement and the value of the t distribution with n − 1 degrees of freedom according to the method described by Bland and Altmann [16]. Agreement was considered statistically significantly different if the bandwidth of the 95% limits of agreement, including the confidence intervals, of either scout method was smaller than the bandwidth of the other scout method.


Fifty-three patients underwent 55 treatment procedures between December 2009 and March 2015 (two patients underwent separate lobar procedures) (Fig. 2). Before treatment, every patient received 99mTc-MAA and 166Ho-scout in a separate procedure (99mTc-MAA interval; median 7 days, range 2–21 days and 166Ho-scout; same day). Thirty-two procedures were excluded from analysis: in 13 procedures, a mismatch in catheter tip positioning was found; in 10 procedures, data was not completely available (one or more missing angiographic images (n = 4); no pre-treatment FDG-PET/CT (n = 2); no post-treatment SPECT/CT (n = 2); 166Ho-scout was not administered (n = 2)), and in nine procedures, the ratio of activity between the injection positions was not similar. A total of 23 procedures in 22 patients were included for analysis (Table 1). In these 22 patients, 71 lesions were analyzed. The mean administered treatment activity of 166Ho-microspheres per procedure was 5,470 MBq (range 1,957–12,897).

Fig. 2

Inclusion flowchart of patient data

Table 1 Baseline characteristics

Figure 3 shows the overall agreement scores of both pre-treatment scans with the 166Ho post-treatment scan, based on the visual assessment of the two nuclear medicine physicians. The median score for 99mTc-MAA was 2.5 compared to 4 for 166Ho-scout (p < 0.001). In 15 of the 23 procedures, overall agreement between 166Ho-scout and 166Ho-therapeutic dose was rated higher than 99mTc-MAA (Fig. 4). 99mTc-MAA showed better overall agreement in five procedures and in three procedures equal agreement was observed. The interrater agreement was moderate with a weighted kappa of 0.52.

Fig. 3

Box plot. Scores of the overall agreement between both 99mTc-MAA and 166Ho-scout and 166Ho-therapeutic dose of all 23 procedures are plotted in a box plot. Median and interquartile lines are indicated. Holmium scout dose performs significantly better than 99mTc-MAA (p < 0.001)

Fig. 4

Example of discrepancy between 99mTc-MAA and 166Ho-therapeutic dose. Despite identical catheter positions (upper row), there is a remarkable difference in activity distribution between the three procedures. SPECT-CT (middle and lower row) shows that the activity distribution in the liver of 166Ho-scout is more similar to the therapy distribution than 99mTc-MAA. Overall agreement of 99mTc-MAA was rated 2.5 compared to 4.5 for 166Ho scout for this patient

Quantitative analysis showed that the overall mean differences in pre- minus post-treatment calculated absorbed dose for all lesions were 16.5 Gy for 99mTc-MAA and 7.5 Gy for 166Ho-scout. For 99mTc-MAA the 95% limits of agreement of the differences were − 164.1 and 197.0 Gy (Fig. 5). 166Ho-scout showed 95% limits of agreement of the differences of − 90.3 and 105.3 Gy. Based on the narrower width of the 95% limits of agreement and no overlap in confidence intervals of the 95% limits of agreement of the 99mTc-MAA (− 197.3 and − 130.8 Gy and 163.8 and 230.3 Gy) and 166Ho-scout (− 108.3 and − 72.3 Gy and 87.3 and 123.4 Gy) Bland-Altman plots, 166Ho scout performed significantly better than 99mTc-MAA.

Fig. 5

Bland-Altman plots for lesion analyses. (1) Difference between 99mTc-MAA and 166Ho-therapeutic dose activity in each lesion is plotted against mean activity in each lesion. (2) Difference between 166Ho-scout and 166Ho-therapeutic dose activity in each lesion is plotted against mean activity in each lesion. The 95% limits of agreement (LoA) are indicated and surrounded by two dotted lines indicating the standard error of the 95% LoA

Quantitative analysis of the normal liver absorbed dose showed that the mean difference in the pre- and post-treatment calculated absorbed dose was 1.3 Gy for 99mTc-MAA and 0.2 Gy for 166Ho-scout (Fig. 6). The 95% limits of agreement of 99mTc-MAA and 166Ho-scout were comparable, − 2.9 and 5.5 Gy for 99mTc-MAA and − 3.6 and 4.1 Gy for 166Ho-scout with overlapping confidence intervals (99mTc-MAA; − 4.2 and − 1.6 Gy and 4.1 and 6.8 Gy, 166Ho-scout; − 4.9 and − 2.4 Gy and 2.9 and 5.3 Gy).

Fig. 6

Bland-Altman plots for healthy-liver segmentation. (1) Difference between 99mTc-MAA and 166Ho-therapeutic dose activity is plotted against mean activity for each procedure. (2) Difference between 166Ho-scout and 166Ho-therapeutic dose activity is plotted against mean activity for each procedure. The 95% limits of agreement (LoA) are indicated and surrounded by two dotted lines indicating the standard error of the 95% LoA


This study showed that treatment planning prior to radioembolization can be improved by using a scout dose of 166Ho-microspheres instead of 99mTc-MAA. The qualitative and quantitative analysis showed that the agreement between 166Ho-scout and 166Ho-therapeutic dose was significantly superior to 99mTc-MAA.

The difference in agreement between scout dose distribution and treatment distribution is subject to several influencing factors. First, as stated before, catheter positioning is known to be a key factor [2]. In order to accurately measure agreement, the catheter tip should be positioned identically for all administrations in each patient to prevent differences in flow. Attempts were made to eliminate this factor by always paying close attention to the exact positioning of the catheter and by retrospectively excluding patients for whom the catheter positions showed suboptimal agreement. However, even with seemingly identical catheter positions on 2D images, the catheter position in 3D may still be different.

Secondly, the assumption of a homogeneous distribution in the normal liver and lesion segmentations is not representative, leading to an overestimation of agreement. From a clinical perspective, normal liver-absorbed dose and tumor-absorbed dose are the most important parameters in terms of safety and efficacy. However, the VOIs of the normal liver compartment cover a much larger volume than the lesion VOI’s and therefore the level of overestimation of the agreement will be higher for this part of the analysis. In the qualitative analysis, agreement was visually analyzed on a more detailed, sub-segmental level. Interestingly, this analysis showed that in 65% of the 23 procedures, overall agreement between 166Ho-scout and 166Ho-therapeutic dose was better than with 99mTc-MAA. In addition, the mean of the overall agreement scores of all procedures of 166Ho-scout was significantly higher compared to 99mTc-MAA.

Thirdly, the width of the standard error of the 95% limits of agreement is strongly influenced by the number of analyzed procedures. Due to strict exclusion criteria, only 23 procedures were eligible for analysis. A larger study would require more patients to undergo two types of treatment-planning administrations, which is a burden to the patients, costly and arguably unethical.

Lastly, technical aspects may have influenced the outcome of this study. Imaging of 166Ho and 99mTc-MAA is inherently different in terms of background noise and resolution, which could have influenced both the qualitative and quantitative analyses. These inherent differences are unavoidable for conducting this study. In addition, the type of gamma camera, reconstruction software and matrix size was not uniform across the study. We think the influence of these factors on the outcome of the analyses is limited. A more important factor is the interval between injections. The injections of 166Ho-scout and 166Ho-therapeutic dose were performed on the same day. It is possible that the scout dose injection induced embolic effects that influenced the distribution of 166Ho-microspheres during the treatment injection later that day. The majority of the analyzed patients were treated with radioembolization for colorectal liver metastases that are known to be relatively hypovascular tumors. Especially in these patients, embolic effects may lead to alterations in microsphere distribution [18]. This may have led to an enhanced disagreement between 166Ho-scout and 166Ho-therapeutic dose. Regardless of the type of scout-dose, embolic effects can be experienced during 166Ho-radioembolization, even though the number of 166Ho-microspheres injected for therapy (approximately 30 million) is lower than the typical number of resin 90Y-microspheres injected (estimated 50 million) [9, 11]. On the other hand, however, the larger time interval between 99mTc-MAA (i.e., approximately 1 week versus same day for 166Ho-scout) and 166Ho-therapeutic dose may have led to interval changes in flow dynamics and thus altered distribution. Any type of scout dose performed on the same day as treatment may be more predictive than scout doses injected earlier. The difference in time interval may also result in 99mTc-MAA being administered by another operator than the operator injecting the 166Ho-therapeutic dose. Administration speed and technique may differ between operators. Also, the administration box used for 166Ho-scout and therapy administration with the possibility to intermittently change between contrast and microsphere injections was not available for 99mTc-MAA injections.

A downside of 166Ho-scout is that it is not as readily available as 99mTc-MAA, which can be easily extracted from a generator. 166Ho-scout needs to be ordered, activated in a nuclear reactor and delivered to the treatment site.

This study focused on intrahepatic distribution, but lung shunt calculation is another important aspect of 166Ho-scout. Elschot et al. showed that a scout dose of 166Ho-microspheres is more accurate for lung shunt calculation on SPECT/CT than 99mTc-MAA [19]. This reduces the chance that a patient is unnecessarily excluded from therapy or receives an unnecessary dose reduction. In addition, Braat et al. studied safety concerns of an unintended extrahepatic deposition of 166Ho-scout. They showed that extrahepatic depositions did not lead to any adverse events in their study. This supported the previously published findings by Prince et al. [8, 20].

Individualized treatment planning becomes increasingly important for patients who are selected for radioembolization. However, pre-treatment activity planning based on 99mTc-MAA lacks dosimetric accuracy and needs improvement in order to increase the clinical benefit of radioembolization treatment. A recent study by Kafrouni et al. showed that body surface area (BSA) based activity planning (i.e., the “BSA-method”) often leads to under-dosing, most likely because it insufficiently corrects for the tumor-to-normal (T/N) uptake ratios [21]. Despite this limitation, the BSA-method currently is the most commonly used treatment planning method [22]. As an alternative to the BSA-method, the so-called partition model can be used. Analysis of SPECT-based biodistribution of 99mTc-MAA is used to account for distribution differences between tumor and non-tumor compartments. This method is known to be a more personalized and accurate treatment planning method. However, the predictive value of 99mTc-MAA seems limited in many cases and the partition model is rarely used in clinical practice. The therapeutic activity choice in our treatment is based on one-compartment modeling or the so-called MIRD model, using an average absorbed dose to the target volume without differentiation between tumor and normal tissue absorbed doses. Analysis of 166Ho-scout and 166Ho-therapeutic dose imaging, together with treatment outcomes in terms of efficacy and safety, will lead to threshold values for personalized dosimetry-based treatment planning, which ultimately needs to be validated in prospective clinical studies. This study showed that 166Ho-scout may serve as a predictive “biomarker” for safe and effective treatment.

In conclusion, both the qualitative and quantitative analyses showed that the intrahepatic distribution of the 166Ho-scout agreed better with the distribution of the therapy dose than 99mTc-MAA, although the comparison has some inherent limitations. These results support the use of a scout dose of 166Ho-microspheres for radioembolization treatment planning.


  1. 1.

    Dhabuwala A, Lamerton P, Stubbs R. Relationship of 99mtechnetium labelled macroaggregated albumin (99mTc-MAA) uptake by colorectal liver metastases to response following selective internal radiation therapy (SIRT). BMC Nucl Med. 2005;5(7).

  2. 2.

    Wondergem M, Smits ML, Elschot M, et al. 99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic Radioembolization. J Nucl Med. 2013;54(8):1294–301.

    CAS  Article  Google Scholar 

  3. 3.

    Ulrich G, Dudeck O, Furth C, et al. Predictive value of Intratumoral 99mTc-macroaggregated albumin uptake in patients with colorectal liver metastases scheduled for Radioembolization with 90Y-microspheres. J Nucl Med. 2013;54(4):516–22.

    CAS  Article  Google Scholar 

  4. 4.

    Ilhan H, Goritschan A, Paprottka P, et al. Predictive value of 99mTc-MAA SPECT for 90Y-labeled resin microsphere distribution in Radioembolization of primary and secondary hepatic tumors. J Nucl Med. 2015;56(11):1654–60.

    CAS  Article  Google Scholar 

  5. 5.

    Seevinck PR, van de Maat GH, de Wit TC, et al. Magnetic resonance imaging-based radiation-absorbed dose estimation of 166Ho microspheres in liver radioembolization. Int J Radiat Oncol Biol Phys. 2012;83(3):437–44.

    Article  Google Scholar 

  6. 6.

    van de Maat GH, Seevinck PR, Elschot M, et al. MRI-based biodistribution assessment of holmium-166 poly(L-lactic acid) microspheres after radioembolisation. Eur Radiol. 2012;23(3):827–35.

    Article  Google Scholar 

  7. 7.

    Elschot M, Nijsen JF, Dam AJ, de Jong HW. Quantitative evaluation of scintillation camera imaging characteristics of isotopes used in liver radioembolization. PLoS One. 2011;6(11):e26174.

    CAS  Article  Google Scholar 

  8. 8.

    Prince JF, van Rooij R, Bol GH, de Jong HW, van den Bosch MA, Lam MG. Safety of a scout dose preceding hepatic radioembolization with 166Ho microspheres. J Nucl Med. 2015;56:817–23.

    Article  Google Scholar 

  9. 9.

    Smits ML, Nijsen JF, van den Bosch MA, et al. Holmium-166 radioembolization for the treatment of patients with liver-metastases: design of the phase I HEPAR trial. J Exp Clin Cancer Res. 2010;29:70.

    Article  Google Scholar 

  10. 10.

    Smits ML, Nijsen JF, van den Bosch MA, et al. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial) a phase 1, dose-escalation study. Lancet Oncol. 2012;13:1025–34.

    CAS  Article  Google Scholar 

  11. 11.

    Prince JF, van den Bosch MA, Nijsen JF, et al. Efficacy of radioembolization with holmium-166 microspheres in salvage patients with liver metastases: a phase 2 study. J Nucl Med. 2017.

  12. 12.

    Elschot M, Smits ML, Nijsen JF, et al. Quantitative Monte Carlo-based holmium-166 SPECT reconstruction. Med Phys. 2013;40(11):112502–12.

    Article  Google Scholar 

  13. 13.

    Bol GH, Kotte AN, van der Heide UA, Lagendijk JJ. Simultaneous multi-modality ROI delineation in clinical practice. Comput Methods Prog Biomed. 2009;96(2):133–40.

    Article  Google Scholar 

  14. 14.

    Fleiss JL, Cohen J. The equivalence of weighted kappa and the intraclass correlation coefficient as a measure of reliability. Educ Psychol Meas. 1973;33(3):613–9.

    Article  Google Scholar 

  15. 15.

    Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–74.

    CAS  Article  Google Scholar 

  16. 16.

    Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1(8476):307–10.

    CAS  Article  Google Scholar 

  17. 17.

    Bland JM, Altman DG. Comparing methods of measurement: why plotting difference against standard method is misleading. Lancet. 1995;346(8982):1085–7.

    CAS  Article  Google Scholar 

  18. 18.

    Boas FE, Bodei L, Sofocleus CT. Radioembolization of colorectal liver metastases: indications, technique, and outcomes. J Nucl Med. 2017;9(58):104S–11S.

    Article  Google Scholar 

  19. 19.

    Elschot M, Nijsen JF, Lam MG, et al. 99mTc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with 166Ho-microspheres. Eur J Nucl Med Mol Imaging. 2014;41(10):1965–75.

    CAS  Article  Google Scholar 

  20. 20.

    Braat AJ, Prince JF, van Rooij R, et al. Safety analysis of holmium-166 microsphere scout dose imaging during radioembolisation work-up: a cohort study. Eur Radiol. 2018;28(3):920–8.

    Article  Google Scholar 

  21. 21.

    Kafrouni M, Allimant C, Fourcade M, et al. Retrospective voxel-based dosimetry for assessing the body surface area model ability to predict delivered dose and radioembolization outcome. J Nucl Med. 2018;59(8):1289–95.

    CAS  Article  Google Scholar 

  22. 22.

    Reinders MT, Mees E, Powerski MJ, et al. Radioembolisation in Europe: a survey amongst CIRSE members. Cardiovasc Intervent Radiol. 2018;41(10):1579–89.

    Article  Google Scholar 

Download references


This study was funded by the Dutch Cancer Society.

Author information



Corresponding author

Correspondence to Marnix G. E. H. Lam.

Ethics declarations

Conflict of interest

The Department of Radiology and Nuclear Medicine of the UMC Utrecht receives royalties and research support from Quirem Medical and Terumo. Marnix Lam is a consultant for BTG, Terumo and Quirem Medical. Maarten Smits has served as a speaker for Sirtex Medical, BTG and Terumo. Arthur Braat has served as a speaker for Sirtex Medical and Terumo. All other authors declare to have no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Oncology – Gastrointestinal

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Smits, M.L.J., Dassen, M.G., Prince, J.F. et al. The superior predictive value of 166Ho-scout compared with 99mTc-macroaggregated albumin prior to 166Ho-microspheres radioembolization in patients with liver metastases. Eur J Nucl Med Mol Imaging 47, 798–806 (2020).

Download citation


  • Technetium-99m-MAA
  • Holmium-166 microspheres
  • Radioembolization
  • SIRT
  • Dosimetry